Novo Nordisk adds four registrations: new molecule trial, CagriSema switch study, real-world dataSep 30Weekly roundup, 7 itemsCagrisemaNNC0705-0002Updated
Novo Nordisk registers Phase 3 trial for denecimig in acquired haemophilia A, plus new Phase 1 studySep 25Weekly roundup, 3 itemsdenecimigNNC0642-1895Updated
Novo Nordisk registers Phase 3 obesity trial in Japan; new CagriSema switch studySep 16Weekly roundup, 2 itemsCagrisemaNNC0487-0111
Novo Nordisk registers two Phase 1 PK trials for zenagamtide and NNC0537-1482Sep 11Weekly roundup, 2 itemsNNC0537-1482Novo Nordisk A/S
Novo Nordisk registers Phase 3 zenagamtide trial in T2D and first-in-human study for NNC0705-0002Sep 1Weekly roundup, 2 itemsNNC0705-0002Novo Nordisk A/S
Novo Nordisk registers real-world cardiometabolic study using Turkish EHR dataAug 24Trial updateNovo Nordisk A/S
Novo Nordisk posts PIONEER TEENS results; registers three new trials for obesity and injectionsAug 21Weekly roundup, 4 itemsNNC0721-8060Novo Nordisk A/S
Novo Nordisk posts results for two semaglutide trials, opens new NNC0487-0111 studyAug 14Weekly roundup, 3 itemsNNC0487-0111Novo Nordisk A/S
Novo Nordisk registers Phase 3 cagrilintide trial; Penn semaglutide study posts resultsAug 4Weekly roundup, 2 itemscagrilintideNovo Nordisk A/S
Novo Nordisk registers Korean MASLD/MASH real-world study and semaglutide back pain trialJul 31Weekly roundup, 2 itemsNovo Nordisk A/Ssemaglutide
Novo Nordisk registers Phase 3 obesity trial for zenagamtide; MTC safety study enrollingJul 22Weekly roundup, 2 itemsNovo Nordisk A/Szenagamtide
Novo Nordisk's two UBT251 drug interaction studies continue recruiting participantsJul 17Weekly roundup, 3 itemsNovo Nordisk A/SUBT251
Novo Nordisk registers Phase 1 study of oral obesity candidate NNC6022-0004Jul 9Trial updateNNC6022-0004Novo Nordisk A/S
Novo Nordisk posts Phase 3 icodec vs. glargine results; registers two observational studiesJul 2Weekly roundup, 3 itemsinsulin icodecNovo Nordisk A/S
Sign in